[Adjunctive therapies (excluding corticosteroids). Site of initial management].
Bacterial meningitis is still a serious disease with a high risk of mortality and sequels. The progress in antibiotic treatment has not improved the prognosis. Thus, optimizing the initial care and the treatment of the most severe cases should improve the outcome. No study has compared the outcome according to the level of care at the admission site. There is evidence that the most severe cases should be managed by critical care units. It seems reasonable to recommend initial admission of common cases to units able to provide intensive care. Most people now agree that fluid restriction has not demonstrated its efficiency, furthermore it might have deleterious effects. However, a fluid overload should be avoided. Maintaining cerebral perfusion is a key issue in the treatment of bacterial meningitis and requires monitoring both arterial blood pressure and intracranial pressure. Intracranial pressure monitoring is probably useful to optimize the treatment of the most severe cases. The aggressive treatments of cerebral edema have not been evaluated but seem, in some limited series, able to improve some life threatening situations. The benefit of systematic glycerol administration needs confirmation. Seizures should be treated with the usual medications. However, drugs with potentially deleterious effects on hemodynamics should be avoided. There is no sufficient evidence to support the administration of a systematic prophylactic treatment. Fever should be treated when above 39.5 degrees C/40 degrees C and in the case of intracranial hypertension. There is no clinical study to explore the modifications of fever on bacterial growth or on inflammation as observed in some experimental studies.
Floret
D
D
Service d'urgence et de réanimation pédiatriques, hôpital Edouard-Herriot, université Claude-Bernard Lyon-1, place d'Arsonval, 59, boulevard Pinel, 69437 Lyon cedex 03, France. daniel.floret@chu-lyon.fr
Javouhey
E
E
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D001929:Brain Edema / Q000209:etiology / Q000517:prevention & control; D002648:Child; D003422:Critical Care; D005334:Fever / Q000188:drug therapy / Q000209:etiology; D006760:Hospitalization; D006801:Humans; D055103:Hypodermoclysis; D019586:Intracranial Hypertension / Q000188:drug therapy / Q000209:etiology; D007427:Intracranial Pressure / Q000187:drug effects / Q000502:physiology; D016920:Meningitis, Bacterial / Q000188:drug therapy* / Q000503:physiopathology; D008991:Monitoring, Physiologic / Q000379:methods; D011379:Prognosis; D012640:Seizures / Q000209:etiology / Q000517:prevention & control